Gilead 거래 GILD

매도
 매수

Gilead 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

Gilead news

Frances Wang 2024 Aug 04, 16:00

The Week Ahead: ISM services, SMCI

CFD Trading
Magnificent Seven earnings take centre stage in the markets this week
Neil Wilson 2024 Apr 19, 01:00

Week ahead: Wall Street’s Magnificent Seven earnings are up

Commodities Forex Indices Shares
Disney is catching up with Netflix
Neil Wilson 2024 Feb 01, 08:03

Week ahead: Earnings season climax

Forex Indices
Consumer inflation
Neil Wilson 2023 Nov 03, 04:01

Week ahead: RBA poised to hike?

Forex Indices
Megacap-tech-stocks.jpg
Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

최신 뉴스

더 보기
Ava Grace 2025 Sep 04, 13:20

US Labor Market Concerns Grow as ADP Data Disappoints and Jobless Claims Rise

Liam James 2025 Sep 04, 13:20

Milan Fed Nomination Hearing: Central Bank Independence Under Scrutiny

Sophia Claire 2025 Sep 04, 09:20

Foreign Exchange Markets' Risk Aversion Spikes Ahead of US Jobs Data

Ava Grace 2025 Sep 04, 08:20

Unlikely Alliance Emerges in Congress to Ban Stock Trading for Lawmakers

Ava Grace 2025 Sep 04, 07:20

UK Gilts: A Generational Buying Opportunity? Analyzing the Bond Market Surge

Ava Grace 2025 Sep 04, 06:20

Optimus Next Gen: A Glimpse at Tesla's New Gold Robot and Musk's Future Vision

Sophia Claire 2025 Sep 04, 06:20

European Nations Weigh Ukraine Security Pledges Amid Deployment Disagreements

Sophia Claire 2025 Sep 04, 05:20

EU-US Trade Agreement Revamp Threatens Fragile Truce, Sparks Concerns

정보

스프레드

0.70

스프레드(%)

0.6173 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 개장

목요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

수요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

139851694080

발행 주식 수

1240809984

수익 날짜 (다음)

2013-01-28

배당수익률

2025-09-29

배당락일

2025-09-15

예상 연간 배당금

3.16

예상 연간 배당수익률

0.028

EPS

5.04

이 상품에 대해 자세히 알아보기

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments

latest_education_articles

더 보기
Trustpilot